| Literature DB >> 30261878 |
Vainess Mbuzi1,2,3, Paul Fulbrook4,5,6, Melanie Jessup4,7.
Abstract
BACKGROUND: Indigenous Australians carry a greater burden of cardiovascular disease than other Australians. A variety of programs has been implemented with the broad aim of improving Indigenous cardiovascular health, however, relatively few have been evaluated rigorously. In terms of effectiveness, understanding how to best manage cardiovascular disease among this population is an important priority. The review aimed to examine the evidence relating to the effectiveness of cardiovascular programs for Indigenous Australians.Entities:
Keywords: Cardiovascular disease; Indigenous Australians; Interventions; Systematic review
Mesh:
Year: 2018 PMID: 30261878 PMCID: PMC6161428 DOI: 10.1186/s12939-018-0867-0
Source DB: PubMed Journal: Int J Equity Health ISSN: 1475-9276
Search strategy in CINAHL
| Search | Search terms |
|---|---|
| S1 Population of interest | ((MH “Indigenous Health”) OR (MH “Aborigines+”) OR (MH “Indigenous Peoples+”) OR (Aborigin* OR Indigenous OR “Torres Strait Islander*” OR “Australoid race” OR Koori* OR Murri* OR “Oceanic ancestry group*”)) |
| S2 Disease | ((MH “Heart Diseases+”) OR (MH “Coronary Arteriosclerosis”) OR (MH “Coronary Disease+”) OR (MH “Cardiovascular Diseases+”) OR (MH “Cardiovascular Risk Factors”) OR (MH “Cardiovascular Abnormalities+”) OR (MH “Cardiac Patients”) OR (Cardiac OR Cardiolog* OR “Heart disease*” OR “Heart failure*” OR Coronar* OR Cardiovascular OR “Heart health” OR “Heart problem*” OR “Heart disorder*”)) |
| S3 Intervention | ((MH “Patient Education+”) OR (MH “Diet+”) OR (MH “Health Services+”) OR (MH “Health Promotion+”) OR (MH “Public Health+”) OR (MH “Epidemiology+”) OR (MH “Treatment Outcomes+”) OR (MH “Rehabilitation+”) OR (MH “Therapeutic Exercise+”) OR (MH “Exercise+”) OR (Prevent* OR Educat* OR Diet* OR Exercise* OR Rehabilitat* OR “Health Promotion” OR “Treatment outcome*” OR “Public health” OR Epidemiology)) |
| S4 Setting | ((MH “Australia+”) OR (MH “Western Australia”) OR (MH “South Australia”) OR (MH “Queensland”) OR (MH “New South Wales”) OR (MH “Australian Capital Territory”) OR (MH “Northern Territory”) OR (MH “Tasmania”) OR (Australia* OR Queensland OR “New South Wales” OR Victoria OR “Australian Capital Territory” OR “South Australia” OR “Western Australia” OR “Northern Territory” OR Tasmania) NOT (Canada OR Columbia)) |
| S6 Design | (“Randomized controlled trial*” OR “controlled clinical trial*” OR “random allocation” OR “double blind method” OR “single blind method” OR “clinical trial*” OR placebo* OR random* OR “research design” OR “comparative stud*” OR “evaluation stud*” OR “follow-up stud*” OR “prospective stud*” OR “cross-over stud*” OR (control* OR prospect* OR volunteer*) OR ((singl* OR doubl* OR treb* OR tripl*) W2 (blind* OR mask*))) |
| S6 | S1 AND S2 AND S3 AND S4 AND S5 |
Fig. 1PRISMA flow diagram: search and study selection
Characteristics of included studies
| Authors, year | Study design | Strategy focus | Intervention | Sample and setting | Method | Outcomes | Comments |
|---|---|---|---|---|---|---|---|
| Burgess, | Interrupted time series study (6 years); pre- and post-measures; 6-monthly follow ups pre- (3 years) and post-intervention (3 years) | Early identification/ preventative | Holistic CVD risk assessment as part of an adult health check | Indigenous participants ( | Questionnaires/charts review/ investigations | Improved delivery of preventive care services; improved medicine prescription; reduction in estimated absolute CVD risk; better and earlier identification of elevated CVD risk. | The program led to better and earlier identification of cardiac risk factors as well as generally improved delivery of preventive care services and cardiac treatment |
| Burgess, | Longitudinal clinical audits of cardiac prevention services; 3 monthly follow-ups for 2 years | Preventative | Chronic conditions management model | Indigenous participants ( | Clinical audit of cardiac prevention services | Increased coverage of Indigenous population CVD risk assessment; assessment of modifiable cardiac risk factors); increased appropriate prescription of medication; achievement of clinical targets for risk reduction | The program demonstrated ability to reduce cardiac risk factors in rural Indigenous populations. It also enabled follow-up of patients |
| Canuto, | Pragmatic RCT | Management/ treatment | 12-week exercise and nutrition program | Indigenous participants (intervention | Implementation of a structured exercise program | Reduction in weight and BMI | Low attendance but intervention had positive effects. Requires understanding the barriers to participation |
| Davey, | Mixed methods | Rehabilitation/ secondary prevention | 8-week supervised exercise and educational session - cardiopulmonary rehabilitation and secondary prevention program | Indigenous participants ( | Implemented an exercise and educational program with Indigenous community | Increased participation in rehabilitation; positive changes in health behaviours, functional exercise capacity and health related quality of life. Decreased weight, BMI, and waist circumference | Community based interventions have multiple positive impacts |
| Davidson, | Mixed methods | Management/ treatment | A partnership model among key education providers, policy makers, non-government organisations, the local area health service and Aboriginal community controlled organisations | Indigenous participants ( | Mixed method evaluation using | Participants reported increased confidence in ability to provide CVD service to community and demonstrated enhanced CVD knowledge: post-course test mean score 70% vs pre-course score 42% | The model was useful in promoting cardiac knowledge in Aboriginal Health Workers while increasing Aboriginal health knowledge in the mainstream health setting. The model forged partnerships. |
| Daws, | Pre- and post -evaluation program | Rehabilitation/ secondary prevention | Working together model of care - (Aboriginal hospital liaison officer and specialist cardiac nurse team) | Aboriginal and Torres Strait Islander participants ( | Retrospective audit | Increased referral rate (15 to 86%) | The partnership model approach to care coordination and system changes that were implemented led to improved attendance at cardiac rehabilitation in the participating group |
| Dimer, | Mixed methods | Rehabilitation | Cardiac rehabilitation program; weekly exercise and education sessions | Indigenous participants ( | Evaluation of exercise and educational program | Decreased weight, BMI, BP, waist girth; improved 6-min walk test | Aboriginal Medical Service based cardiac rehabilitation proved to be effective in improving attendance, and cardiac risk factor and health management |
| Peiris | Parallel arm cluster-randomized controlled trial | Management/ treatment | Computer-guided quality improvement intervention | Aboriginal and Torres Strait Islander participants ( | Implementation of computerised screening and management algorithm | The intervention was associated with improved overall risk factor measurements | There was minimal support required to implement the tool and had positive effects on improving cardiac risk measurement |
BMI body mass index, BP blood pressure, CVD cardiovascular disease
Critical appraisal of randomised controlled trials
| JBI checklist criteria (potential bias) | Studies | |
|---|---|---|
| Canuto | Peiris | |
| 1. Was true randomization used for assignment of participants to treatment groups? (selection bias) | Yes | Yes |
| 2. Was allocation to treatment groups concealed? (selection bias) | No | No |
| 3. Were treatment groups similar at the baseline? (selection bias/design bias) | Yes | Yes |
| 4. Were participants blind to treatment assignment? (performance bias) | No | No |
| 5. Were those delivering treatment blind to treatment assignment? (performance/detection bias) | No | No |
| 6. Were outcomes assessors blind to treatment assignment? (ascertainment bias) | No | Yes |
| 7. Were treatments groups treated identically other than the intervention of interest? (systematic difference/containment bias) | Yes | Yes |
| 8. Was follow-up complete, and if not, were strategies to address incomplete follow-up utilized? (attrition bias) | Yes | Yes |
| 9. Were participants analysed in the groups to which they were randomized? (intention to analysis) | Yes | Yes |
| 10. Were outcomes measured in the same way for treatment groups? (instrumentation/testing effects threats) | Yes | Yes |
| 11. Were outcomes measured in a reliable way? (measurement bias) | Yes | Yes |
| 12. Was appropriate statistical analysis used? (performance/detection bias) | Yes | Yes |
| 13. Was the trial design appropriate, and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial? (design bias) | Yes | Yes |
| Total (%) and quality ratinga | 9/13 (69%) | 10/13 (77%) |
aGood: at least 80%, moderate: 50–80%; poor: less than 50%
Results of critical appraisal of quasi-experimental studies
| JBI checklist criteria (potential bias and threat) | Studies | |||||
|---|---|---|---|---|---|---|
| Burgess | Burgess | Davey | Davidson | Daws | Dimer | |
| 1. Is it clear in the study what is the ‘cause’ and what is the ‘effect’ (i.e. there is no confusion about which variable comes first)? (causation/reverse causation) | Yes | Yes | Yes | Yes | Yes | Yes |
| 2. Were the participants included in any comparisons similar? (selection bias) | Yes | Yes | Yes | Yes | Yes | Yes |
| 3. Were the participants included in any comparisons receiving similar treatment/care, other than the exposure or intervention of interest? (history threat/systematic difference/ contamination bias) | Yes | Yes | Yes | Yes | Yes | Yes |
| 4. Was there a control group? (measurement bias) | No | No | No | No | No | No |
| 5. Were there multiple measurements of the outcome both pre and post the intervention/exposure? (maturation threat, regression to the mean) | Yes | No | Yes | Yes | No | Yes |
| 6. Was follow-up complete, and if not, was follow-up adequately reported and strategies to deal with loss to follow-up employed? (attrition bias) | Yes | Yes | Yes | Yes | Yes | Yes |
| 7. Were the outcomes of participants included in any comparisons measured in the same way? (instrumentation/testing effects threats) | Yes | Yes | Yes | Yes | No | Yes |
| 8. Were outcomes measured in a reliable way? (detection/instrument/measurement bias) | Yes | Yes | Yes | Yes | No | Yes |
| 9. Was appropriate statistical analysis used? (performance/detection bias) | Yes | No | Yes | Yes | No | Yes |
| Total (%) and quality ratinga | 8/9 (88%) | 6/9 (67%) | 8/9 (88%) | 8/9 (88%) | 4/9 (44%) | 8/9 (88%) |
aGood: at least 80%, moderate: 50–80%; poor: less than 50%
Significant results of individual studies
| Author year Study design | Sample size | Model or test used | Outcomes | Significance | Effect size | ||
|---|---|---|---|---|---|---|---|
| Measure | Result | ||||||
| Canuto et al., 2012 | Regression analysis; adjusted for all potential confounders | T1-T2 mean weight change (kg) | −1.65 (95% CI -3.27 - -0.03) | 0.046 | NR | ||
| T1-T2 mean BMI change (kg/m2) | −0.66 (95% CI -1.27 - -0.05) | 0.035 | NR | ||||
| Peiris et al., 2015 | Repeated measures | Appropriate screening for CVD (%) | Exp: 62.8 | 0.02 | RR 1.25 | ||
| CVD risk screening small service (< 500) (%) | Exp: 59.8 | 0.02 | 1.62 | ||||
| HR cohort: antiplatelet medication prescription escalation (%) | Exp: 17.9 | < 0.001 | RR 4.80 | ||||
| HR cohort: lipid-lowering medication prescription escalation (%) | Exp: 19.2 | < 0.001 | RR 3.22 | ||||
| HR cohort: BP-lowering medication prescription escalation (%) | Exp: 23.3 | 0.02 | RR 1.89 | ||||
| HR cohort: proportion obtaining guideline BP targets (%) | Exp: 61.0 | 0.05 | 1.10 | ||||
| Burgess et al., 2011 [ | Repeated measures | Delivery of CVD preventive services (%) | Baseline: 30 | < 0.001 | NR | ||
| Proportion of evidence-based CVD services delivered (%) | Baseline: 29 | < 0.001 | NR | ||||
| Prescription of all CVD related medication (%) | Baseline: 28 | < 0.001 | NR | ||||
| Prescription of anti-platelet medication (%) | Baseline: 4.7 | < 0.001 | NR | ||||
| Prescription of lipid-lowering medication (%) | Baseline: 6.3 | < 0.001 | NR | ||||
| Prescription of ACEi/ARB medication (%) | Baseline: 25.0 | < 0.001 | NR | ||||
| Prescription of oral hypoglycaemic medication (%) | Baseline: 17.2 | 0.04 | NR | ||||
| Number of cigarettes smoked per day ( | At health check: 3.5 | < 0.001 | NR | ||||
| Waist circumference (cm) ( | At health check: 98.3 | 0.04 | NR | ||||
| HDL cholesterol (mmol/L) ( | At health check: 1.01 | 0.001 | NR | ||||
| Ratio of total to HDL ( | At health check: 5.7 | < 0.001 | NR | ||||
| Expected post health check 5-year CVD risk (%) ( | At health check: 3.5 | < 0.001 | NR | ||||
| Expected post health check 10-year CVD risk (%) ( | At health check: 9.5 | < 0.001 | NR | ||||
| Mean estimated absolute 10-year CVD risk ( | Expected at health check review: 10.2 | 0.004 | NR | ||||
| Burgess et al., 2015 [ | Population: 49 primary health care services ( | Post intervention descriptive measures | CVD risk assessment: proportion of population (%) | Pre: 26.0 ( | NR | – | |
| HR cohort ( | Post: 93.3 ( | NR | – | ||||
| HR cohort ( | Post: 66.8 ( | NR | – | ||||
| HR cohort ( | Post: 56.6 ( | NR | – | ||||
| HR cohort ( | Post: 96.5 ( | NR | – | ||||
| HR cohort ( | Post: 54.8 ( | NR | – | ||||
| HR cohort ( | Post: 39.6 ( | NR | – | ||||
| HR cohort ( | Post: 50.0 ( | NR | – | ||||
| Davey et al., 2014 [ | Repeated measures | Weight change (kg) | −0.8 (95% CI -.0.01 - -1.6) | NS – value NR | Cohen’s | ||
| BMI change (kg m−2) | −0.3 (95% CI -0.01 - -0.06) | NS – value NR | Cohen’s | ||||
| Waist circumference change (cm) | −3.6 (95% CI -2.5 - -4.7) | NS – value NR | Cohen’s | ||||
| Incremental Shuttle Walk Test change (m) | 106.2 (95% CI 79.1–133.2) | NS – value NR | Cohen’s | ||||
| 6 Minute Walk Test change (m) | 55.7 (95% CI 37.8–73.7) | NS – value NR | Cohen’s | ||||
| Timed up and go test change (sec) | −0.8 (95% CI -0.5 - -1.1) | NS – value NR | Cohen’s | ||||
| Quality of life (SF 36) change | General health | 9.7 (95% CI 4.4–14.9) | S – value NR | NR | |||
| Bodily pain | 7.4 (95% CI 0.5–14.4) | S – value NR | NR | ||||
| Vitality | 15.3 (95% CI 9.6–21.1) | S – value NR | NR | ||||
| Social functioning | 8.5 (95% CI 0.8–16.3) | S – value NR | NR | ||||
| Role emotional | 13.5 (95% CI 1.0–26.1) | S – value NR | NR | ||||
| Mental health | 14.2 (95% CI 8.6–19.9) | S – value NR | NR | ||||
| Davidson et al., 2008 [ | Repeated measures | Knowledge score (range 1–25) | Pre: 9.93 (SD 4.02) | < 0.001 | NR | ||
| Confidence in knowledge score | Pre: 4.46 (SD 1.84) | < 0.001 | NR | ||||
| Confidence in skills score | Pre: 4.29 (SD 2.75) | < 0.001 | NR | ||||
| Confidence in communication score | Pre: 5.52 (SD 2.39) | < 0.001 | NR | ||||
| Daws et al., 2014 [ | Pre: | Retrospective audit | Referral for cardiac rehabilitation (%) | Pre ( | NR | – | |
| Attendance for cardiac rehabilitation (%) | Pre ( | NR | – | ||||
| Dimer et al., 2013 [ | Population | Repeated measures | BMI (kg m−2) | Pre: 34.0 (SD 5.1) | < 0.05 | NR | |
| Waist girth (cm) | Pre: 112.9 (SD 13.6) | < 0.01 | NR | ||||
| Sample subset (program completion) | Systolic BP (mm Hg) | Pre: 135 (SD 20) | < 0.01 | NR | |||
| Diastolic BP (mm Hg) | Pre: 78 (SD 12) | < 0.05 | NR | ||||
| 6 Minute Walk Test distance (m) | Pre: 296 (SD 115) | < 0.01 | NR | ||||
ACEi angiotensin converting enzyme, ARB angiotensin receptor blocker, BMI body mass index, BP blood pressure, Con control, CVD cardiovascular disease, Exp experiment, HDL high density lipoprotein, HR high risk, NR not reported, Quasi quasi-experimental study, RCT randomised controlled trial, RR relative risk, S significant, SD standard deviation